Notable Mergers and Acquisitions of the Day 5/8: COV/VNUS
More News related to COV
- Covidien to Present at Piper Jaffray Health Care Conference
- Covidien (COV) Announces FDA Extends Review of NDA for Exalgo
- FDA Extends Review of NDA for Exalgo(TM)
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Covidien (COV) Posts Q4 adj.-EPS of $0.72, Tops by 4c
More News related to VNUS
- Roth Capital Downgrades VNUS Medical Technologies (VNUS) to Hold
- William Blair Downgrades VNUS Medical (VNUS) to Market Perform
- Notable Mergers and Acquisitions of the Day 5/8: COV/VNUS
- Morning Movers 5/8: FTWR, RDNT, VNUS, AXL, FITB, LEAP Higher; DPTR, CROX, INAP, HUN, GNW Lower
- Covidien (COV) To Acquire VNUS Medical (VNUS) For $29/Share
More News related to Special Reports
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
- Covidien (NYSE: COV) reached a definitive agreement to acquire VNUS Medical Technologies, Inc. (NASDAQ: VNUS) for $29 per share, or $440 million net of cash.
Shares of VNUS closed at $21.32 yesterday.
Assuming a second calendar quarter closing, Covidien expects this transaction to dilute fiscal 2009 GAAP earnings per share, primarily due to a one-time charge for in-process research and development (IPR&D). On a non-GAAP basis, excluding IPR&D, the transaction is expected to be slightly dilutive to 2009 earnings per share; however, the underlying strength of Covidien’s existing businesses is expected to offset this dilution. As a result, Covidien does not anticipate this transaction will have a material impact on its fiscal 2009 sales or operating margin outlook.
Related Categories
Special ReportsStocks Mentioned
+0.55Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
